{"id":"ifosfamide-or-dacarbazine","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"50–90","effect":"Nausea and vomiting"},{"rate":"5–40","effect":"Hemorrhagic cystitis (ifosfamide)"},{"rate":"10–30","effect":"Neurotoxicity/encephalopathy (ifosfamide)"},{"rate":"40–60","effect":"Alopecia"},{"rate":"5–15","effect":"Hepatotoxicity"},{"rate":"5–10","effect":"Renal dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ifosfamide is a nitrogen mustard alkylating agent that forms covalent bonds with DNA, causing interstrand and intrastrand cross-links that block DNA replication and transcription. Dacarbazine is a triazene compound that requires hepatic metabolism to generate an active methylating species, which similarly alkylates DNA. Both agents are non-cell-cycle-specific and induce apoptosis in rapidly dividing cancer cells.","oneSentence":"Ifosfamide and dacarbazine are alkylating agents that cross-link DNA to prevent cancer cell replication, while dacarbazine also acts as a prodrug requiring metabolic activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:15.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Soft tissue sarcoma (ifosfamide component)"},{"name":"Melanoma (dacarbazine component)"},{"name":"Lymphoma (both agents)"}]},"trialDetails":[{"nctId":"NCT04031677","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-01-20","conditions":"Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":250},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT04307277","phase":"PHASE3","title":"Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2020-10-09","conditions":"Soft Tissue Sarcoma","enrollment":600},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT06835049","phase":"PHASE2","title":"Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2025-10-27","conditions":"Sarcoma,Soft Tissue","enrollment":24},{"nctId":"NCT01864109","phase":"PHASE2","title":"Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Newly Diagnosed Ewing Sarcoma","enrollment":83},{"nctId":"NCT03805022","phase":"PHASE3","title":"Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2019-02-14","conditions":"Non-metastatic Soft-tissue Sarcoma, Resectable","enrollment":351},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT03277924","phase":"PHASE1, PHASE2","title":"Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas","status":"COMPLETED","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2017-05-31","conditions":"Soft Tissue Sarcoma, Bone Sarcoma","enrollment":197},{"nctId":"NCT02049905","phase":"PHASE3","title":"Phase 3 Study to Treat Patients With Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2014-01","conditions":"Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma","enrollment":433},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT03342300","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma","status":"WITHDRAWN","sponsor":"Peking University People's Hospital","startDate":"2017-11-06","conditions":"Progression-free Survival, Overall Survival, Toxicity","enrollment":""},{"nctId":"NCT01576692","phase":"PHASE1","title":"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-04","conditions":"Neuroblastoma","enrollment":34},{"nctId":"NCT00960063","phase":"PHASE1","title":"A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11-11","conditions":"Neoplasms, Solid Tumors, Bone Cancer","enrollment":4},{"nctId":"NCT00089544","phase":"PHASE2","title":"Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-06-17","conditions":"Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7","enrollment":23},{"nctId":"NCT00920153","phase":"PHASE3","title":"Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-05","conditions":"Lymphoma","enrollment":442},{"nctId":"NCT00025064","phase":"PHASE2","title":"Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2000-01","conditions":"Lymphoma","enrollment":260},{"nctId":"NCT00410631","phase":"PHASE3","title":"Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma","status":"UNKNOWN","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2004-10","conditions":"Neuroblastoma","enrollment":642},{"nctId":"NCT00017225","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"1997-05","conditions":"Neuroblastoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ifosfamide or dacarbazine","genericName":"Ifosfamide or dacarbazine","companyName":"Institut Bergonié","companyId":"institut-bergoni","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ifosfamide and dacarbazine are alkylating agents that cross-link DNA to prevent cancer cell replication, while dacarbazine also acts as a prodrug requiring metabolic activation. Used for Soft tissue sarcoma (ifosfamide component), Melanoma (dacarbazine component), Lymphoma (both agents).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}